Unlearn has developed the first machine learning (ML) platform for creating Intelligent Control Arms with Digital Twins through its proprietary DiGenesis™ process, allowing drug developers to dramatically improve clinical evidence and trial power, while lowering the risk of trial failure, thereby increasing confidence in clinical trial results. Unlearn is working closely with biopharmaceutical and medical device companies as well as regulators to ensure its methods meet the highest scientific and regulatory standards.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/21/20 | $12,000,000 | Series A |
DCVC Mubadala Capital | undisclosed |
| 11/05/20 | $3,000,000 | Series A Extension |
Alumni Ventures Group Eisai  EPIC Ventures | undisclosed |
| 04/19/22 | $50,000,000 | Series B |
8VC DCVC Insight Venture Partners Mubadala Capital Radical Ventures | undisclosed |
| 02/08/24 | $50,000,000 | Series C |
Altimeter Capital EPIC Ventures Mubadala Capital Necessary Ventures Radical Ventures Wittington Ventures | undisclosed |
